Baker McKenzie Legal Advisor to the Banks in Vicore Pharma’s SEK 782 Million Rights Issue and SEK 100 Million Primary Issuance of Shares

Vicore Pharma Holding AB has carried out a rights issue of approximately SEK 782 million as well as a primary issuance of shares of approximately SEK 100 million.

Vicore Pharma is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. The company's shares are listed on Nasdaq Stockholm's main market (VICO).

In both transactions, Pareto Securities acted as Sole Global Coordinator and Joint Bookrunner while Zonda Partners acted as Joint Bookrunner. Baker McKenzie acted as legal advisor to Pareto Securities and Zonda Partners in both transactions with an international capital markets team consisting of Joakim Falkner, Olof Larsson and Monica Ericson in Stockholm as well as Adam Farlow in London.